Journal of Clinical Oncology, Vol 9, 381-388, Copyright © 1991 by American Society of Clinical Oncology
Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma
C Dittrich, E Dittrich, P Sevelda, M Hudec, H Salzer, T Grunt and J Eliason
Department of Chemotherapy, University of Vienna, Austria.
A retrospective analysis was performed to investigate the prognostic value
of growth in a human tumor clonogenic assay system for 84 ovarian cancer
patients. A significant difference in survival probability (determined by
the method of Kaplan-Meier) was found by univariate analysis between
patients with ovarian carcinoma whose tumors manifested clonogenic growth
(defined as growth of greater than or equal to five colonies per plate) and
patients whose tumors did not grow. Clonogenic growth in vitro was
associated with worse prognosis (P = .007, log-rank test). A number of
generally accepted prognostic factors, International Federation of
Gynecology and Obstetrics (FIGO) stage (P = .003), residual tumor mass (P
less than .001), and grade (P = .011), were also of prognostic importance
in our patient population. Multivariate analysis, based on the Cox
regression model, identified clonogenic growth as a significant independent
prognostic parameter in ovarian carcinoma (P = .031), in addition to the
conventional risk factors. Estimation of survival of individual patients
was best accomplished by combining the factors of residual tumor mass (P
less than .05), age (P less than .01), and clonogenic growth (P less than
.05) (in sequence of decreasing potential of risk).
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
